Physician profile
Anthony K Jackson
NPI 1366413114
$1,661.97
in general payments reported to CMS, 2019-2025
21 companies · $582 in 2025
The $582 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.57 · 2022: $172 · 2023: $279 · 2024: $603 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,464.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $562.37 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $288.88 | 2024-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $239.32 | 2022-2025 | |
| Pfizer INC. | $83.92 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $68.45 | 2024-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $63.81 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.82 | 2023-2025 | Xifaxan |
| Abiomed | $49.12 | 2025 | |
| Xeris Pharmaceuticals, INC. | $34.55 | 2022 | |
| Dexcom, INC. | $28.79 | 2022 | |
| Janssen Pharmaceuticals, INC | $26.43 | 2023-2024 | Xarelto |
| Lundbeck LLC | $20.49 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $19.38 | 2023 | Gattex |
| Astellas Pharma US INC | $17.11 | 2025 | Veozah |
| Axsome Therapeutics, INC. | $15.80 | 2025 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.43 | 2023 | Steglatro, Belsomra, Januvia |
| Insulet Corporation | $15.31 | 2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $14.89 | 2025 | Airsupra |
| Lilly USA, LLC | $14.58 | 2025 | Kisunla |
| Bayer Healthcare Pharmaceuticals INC. | $12.68 | 2022 | |
| Sanofi-Aventis U.S. LLC | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.